CLDN18 and gastric cancer: Importantly, after CLDN18-ARHGAP26 was introduced, considerable resistance to 5-fluorouracil and oxaliplatin was observed in a number of gastric cancer cell lines, which may account for the poor drug response of patients harboring this fusion product (176–180).